2738376-81-1
Chemical Structure
C22 Glucosylceramide (d18:1/22:0)-d4
- CAS No.: 2738376-81-1
- Formula:C46H85D4NO8
- Molecular Weight:788.23
InChIKey: YIGARKIIFOHVPF-MFKLBOLNSA-N
SMILES: O[C@H]1[C@@H]([C@H](O[C@H]([C@@H]1O)OC[C@H](NC(CCCCCCCCCCC([2H])(C([2H])(CCCCCCCCC)[2H])[2H])=O)[C@@H](/C=C/CCCCCCCCCCCCC)O)CO)O
Biological Activity: C22 Glucosylceramide (d18:1/22:0)-d4 is deuterium labeled C22 Glucosylceramide (d18:1/22:0) (HY-164236). C22 Glucosylceramide (d18:1/22:0) is a bioactive sphingolipid composed of a d18:1 sphingoid base and a 22:0 fatty acid chain. C22 Glucosylceramide (d18:1/22:0) specifically exists in Doxorubicin (HY-15142A)-sensitive cancer cells, and its circulating concentration is positively correlated with the incidence of cardiovascular events. C22 Glucosylceramide (d18:1/22:0) has been widely used in research related to cardiovascular diseases, hypercholesterolemia, metabolic syndrome, breast adenocarcinoma and other fields[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
C22 Glucosylceramide (d18:1/22:0)-d4 | 98% | C22 Glucosylceramide (d18:1/22:0)-d4 is deuterium labeled C22 Glucosylceramide (d18:1/22:0) (HY-164236). C22 Glucosylceramide (d18:1/22:0) is a bioactive sphingolipid composed of a d18:1 sphingoid base and a 22:0 fatty acid chain. C22 Glucosylceramide (d18:1/22:0) specifically exists in Doxorubicin (HY-15142A)-sensitive cancer cells, and its circulating concentration is positively correlated with the incidence of cardiovascular events. C22 Glucosylceramide (d18:1/22:0) has been widely used in research related to cardiovascular diseases, hypercholesterolemia, metabolic syndrome, breast adenocarcinoma and other fields. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
C22 Glucosylceramide (d18:1/22:0) | 99% | C22 Glucosylceramide (d18:1/22:0) is a bioactive sphingolipid composed of a d18:1 sphingoid base and a 22:0 fatty acid chain. C22 Glucosylceramide (d18:1/22:0) specifically exists in Doxorubicin (HY-15142A)-sensitive cancer cells, and its circulating concentration is positively correlated with the incidence of cardiovascular events. C22 Glucosylceramide (d18:1/22:0) has been widely used in research related to cardiovascular diseases, hypercholesterolemia, metabolic syndrome, breast adenocarcinoma and other fields. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief]
- [2]. Shammout ODA, et al. Comparative sphingolipidomic analysis reveals significant differences between doxorubicin-sensitive and -resistance MCF-7 cells. PLoS One. 2021;16(10):e0258363. Published 2021 Oct 12. [Content Brief]
- [3]. Calzada C, et al. Role of circulating sphingolipids in lipid metabolism: Why dietary lipids matter. Front Nutr. 2023;9:1108098. Published 2023 Jan 11. [Content Brief]
- [4]. Kwon YJ, et al. Effect of Korean Red Ginseng on Plasma Ceramide Levels in Postmenopausal Women with Hypercholesterolemia: A Pilot Randomized Controlled Trial. Metabolites. 2021;11(7):417. Published 2021 Jun 24. [Content Brief]
